Red Lake Nation News - Babaamaajimowinan (Telling of news in different places)

COVID-19 drug price deemed 'reasonable'


Gilead Sciences via AP – via AP

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States.

California's Gilead Sciences announced pricing on Monday for the first drug authorized to treat COVID-19 in the United States, and industry observers did not immediately pass out from sticker shock.

The price range for the drug remdesivir - $3,120 for commercially insured U.S. patients, and $2,340 for government programs here and abroad - was in the neighborhood of the pricing suggestions announced previously by the independent Institute for Clinical and Economic Review (ICER) in Boston.

"Gilead's pricing announcement demonstrates restraint and a promising precedent for future drug pricing during a pandemic," ICER President Dr. Steven Pearson said in a statement. "The price is largely in line with ICER's independent assessment suggesting that a price of approximately $2,800 would be reasonable in proportion to the added benefits for patients and the cost offsets in the health system."


Reader Comments


Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2020

Rendered 11/22/2020 19:47